Pall Corporation

Join Us for Our Two-Part Gene Therapy Webinar Series

Meet the authors from the Ebook: Insights on Successful Gene Therapy Manufacturing and Commercialization

In this webinar series, hear directly from the authors on various topics related to gene therapy manufacturing and commercialization, the current state of the industry and how we can continue to advance these life-changing medicines.

Webinars Available

Webinar 1: Gene Therapy Downstream Manufacturing, Scale-up and Best Practices

  • Tuesday, March 9 - 8:00am PST | 11:00am EST | 4:00pm GMT
  • Thursday, March 11 - 9:00am CET | 1:30pm IST | 4:00pm CST | 5:00pm JST
  • Tuesday, Oct 06- 08:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST
  • Thursday, Oct 22 - 08:00 CEST | 11:30 IST | 14:00 SGT | 15:00 JST
Duration:
1 Hour
Summary:

Gene therapies provide innovative options for treating patients, particularly where other traditional therapeutics have been ineffective. The industry continues to grow and mature from research to approved therapeutics. The latest industry trends and innovations have been detailed in the ebook, "Insights on Successful Gene Therapy Manufacturing and Commercialization" where thought leaders share their perspectives.

In this panel webinar series, hear directly from the authors on various topics related to gene therapy manufacturing and commercialization, the current state of the industry and how we can continue to advance these life-changing medicines.

Speakers:
...

Moderator:

Brandy Sargent  

Editor in-chief 

Cell Culture Dish & Downstream Column  

Brandy Sargent is the Editor in-chief and frequent author of The Cell Culture Dish and The Downstream Column. She has worked in the biotechnology industry for over twenty years, first in corporate communications and public relations, then in technical sales and marketing, and most recently as a writer and publisher. She strives to introduce topics that are interesting, thought provoking, and possible starting points for discussion by the biomanufacturing community. She has been fascinated by the different applications of biotechnology since she first started working in the industry and continues to be fascinated as the industry evolves.
...

Speaker:

Tony Hitchcock 

Technical Director 

Cobra Biologics 

Tony Hitchcock has over 35 years of experience in the large-scale manufacture of biopharmaceuticals. As a founding staff member of Cobra, Mr. Hitchcock has been responsible for the development of much of Cobra’s manufacturing technologies in the field of DNA and virus production. He has held a number of senior roles, managing both manufacturing and development functions within the company, working on over 40 programmes for the development of novel therapeutic products including protein, recombinant virus, bacteriophage and plasmid DNA products.

His current role is based in the commercial group and supports external collaboration and outreach activities.
...

Speaker:

Clive Glover, PhD  

Director, Gene Therapy Strategy 

Pall Corporation 

Dr. Clive Glover is Director of Gene Therapy Strategy at Pall Corporation, part of Danaher. Clive has wide ranging experience developing manufacturing tools for the cell and gene therapy space including stem cells, T cell therapies and viral vector production. He has held business development, marketing and innovation positions at STEMCELL Technologies, GE Healthcare Lifesciences (now Cytiva) and Pall Corporation. He obtained his PhD in Genetics from the University of British Columbia.
...

Speaker:

Mark Schofield, PhD  

Senior R&D Manager 

Pall Corporation  

Dr. Mark Schofield holds a Ph.D. from the University of Dundee. He has 15 years’ experience in R&D and new product development for biopharma related industries. He currently leads the chromatography applications team at Pall developing continuous processing solutions.

Webinar 2: Gene Therapy Upstream Manufacturing, Scale-up and Best Practices

  • Tuesday, March 16 - 8:00am PST | 11:00am EST | 3:00pm GMT
  • Thursday, March 18 - 9:00am CET | 1:30pm IST | 4:00pm CST | 5:00pm JST
  • Tuesday, Oct 06- 08:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST
  • Thursday, Oct 22 - 08:00 CEST | 11:30 IST | 14:00 SGT | 15:00 JST
Duration:
1 Hour
Summary:

Gene therapies provide innovative options for treating patients, particularly where other traditional therapeutics have been ineffective. The industry continues to grow and mature from research to approved therapeutics. The latest industry trends and innovations have been detailed in the ebook, "Insights on Successful Gene Therapy Manufacturing and Commercialization" where thought leaders share their perspectives.

In this panel webinar series, hear directly from the authors on various topics related to gene therapy manufacturing and commercialization, the current state of the industry and how we can continue to advance these life-changing medicines.

Speakers:
...

Moderator:

Brandy Sargent  

Editor in-chief 

Cell Culture Dish & Downstream Column  

Brandy Sargent is the Editor in-chief and frequent author of The Cell Culture Dish and The Downstream Column. She has worked in the biotechnology industry for over twenty years, first in corporate communications and public relations, then in technical sales and marketing, and most recently as a writer and publisher. She strives to introduce topics that are interesting, thought provoking, and possible starting points for discussion by the biomanufacturing community. She has been fascinated by the different applications of biotechnology since she first started working in the industry and continues to be fascinated as the industry evolves.
...

Speaker:

Tony Hitchcock 

Technical Director 

Cobra Biologics 

Tony Hitchcock has over 35 years of experience in the large-scale manufacture of biopharmaceuticals. As a founding staff member of Cobra, Mr. Hitchcock has been responsible for the development of much of Cobra’s manufacturing technologies in the field of DNA and virus production. He has held a number of senior roles, managing both manufacturing and development functions within the company, working on over 40 programmes for the development of novel therapeutic products including protein, recombinant virus, bacteriophage and plasmid DNA products.

His current role is based in the commercial group and supports external collaboration and outreach activities.
...

Speaker:

Don Startt  

Director of Upstream Process Development 

REGENXBIO 

Don Startt leads the upstream process development group for REGENXBIO. His team is responsible for the development, optimization, and scale-up of AAV gene therapy manufacturing processes. Prior to his current position, he has held roles at REGENXBIO, GSK and Human Genome Sciences in various CMC-related positions including Manufacturing Sciences, Project Management, Quality, Operations and Facility Design working on biotechnology-based processes and products at all lifecycle stages.
...

Speaker:

Clive Glover, PhD  

Director, Gene Therapy Strategy 

Pall Corporation 

Dr. Clive Glover is Director of Gene Therapy Strategy at Pall Corporation, part of Danaher. Clive has wide ranging experience developing manufacturing tools for the cell and gene therapy space including stem cells, T cell therapies and viral vector production. He has held business development, marketing and innovation positions at STEMCELL Technologies, GE Healthcare Lifesciences (now Cytiva) and Pall Corporation. He obtained his PhD in Genetics from the University of British Columbia.
...

Speaker:

Byron Rees  

Senior Manager, Scientific Laboratory Services 

Pall Corporation  

Byron received his BSc in Pharmacology from the University of Portsmouth UK. He has gone on to work in QC for microbiology and analytical chemistry at Pfizer. Since joining Pall in 2006 Byron has worked on all of Pall’s bioreactor technology developments and been the lead for R&D Applications on the stirred tank range of bioreactors.

Currently Byron manages the UK Pall Biotech Process Development laboratory where he is responsible for upstream and downstream process development projects in gene therapy, vaccine and monoclonal antibody production.
...

Speaker:

Alengo Nyamay’antu  

Scientific Communication Specialist

Polyplus-transfection SA  

Alengo Nyamay’antu is a Scientific Communication Specialist at Polyplus-transfection SA, the leading biotechnology company that supports Gene and Cell therapy, biologics manufacturing and life science research with innovative nucleic acid transfection solutions. Alengo completed her MSc in structural and functional biochemistry at the University of Lyon and went on to specialize in protein biochemistry at the University of Manchester. She then continued to develop and widen her scientific and communication skills by joining the Max Planck Institute for Biomedicine as a postdoctoral researcher.

Covid-19 and the Vaccines Route for Eradicating the Disease

  • Tuesday, Oct 06- 08:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST
  • Thursday, Oct 22 - 08:00 CEST | 11:30 IST | 14:00 SGT | 15:00 JST
  • Tuesday, Oct 06- 08:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST
  • Thursday, Oct 22 - 08:00 CEST | 11:30 IST | 14:00 SGT | 15:00 JST
Duration:
2 Hours
Summary:

This diversity in the type of vaccine antigen, along with the inherent variation in the targets, have created challenges for vaccine manufacturers when compared to a relatively small number of platform processes that exist for other biotherapeutic production processes

Accelerating vaccine development and manufacturing by coupling research advances in vaccine technology with systems that support agility through a Quality by Design approach is critical to deliver life-saving immunizations to those in need globally.

Each class of vaccine presents specific process development and manufacturing challenges, and the scale of production varies depending upon the targeted disease. As a result, there is no single vaccine manufacturing approach.

There are, however, flexible technologies that can meet each of the challenges during process development and at GMP scale. These customizable technologies can be applied separately but can also be combined to design robust, integrated, flexible platforms that support rapid process development and safeguard the quality of life-protecting vaccines, where closed-systems and aseptic processing is essential.

Speakers:
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.

Covid-19 and the Vaccines Route for Eradicating the Disease

  • Tuesday, Oct 06- 08:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST
  • Thursday, Oct 22 - 08:00 CEST | 11:30 IST | 14:00 SGT | 15:00 JST
  • Tuesday, Oct 06- 08:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST
  • Thursday, Oct 22 - 08:00 CEST | 11:30 IST | 14:00 SGT | 15:00 JST
Duration:
2 Hours
Summary:

This diversity in the type of vaccine antigen, along with the inherent variation in the targets, have created challenges for vaccine manufacturers when compared to a relatively small number of platform processes that exist for other biotherapeutic production processes

Accelerating vaccine development and manufacturing by coupling research advances in vaccine technology with systems that support agility through a Quality by Design approach is critical to deliver life-saving immunizations to those in need globally.

Each class of vaccine presents specific process development and manufacturing challenges, and the scale of production varies depending upon the targeted disease. As a result, there is no single vaccine manufacturing approach.

There are, however, flexible technologies that can meet each of the challenges during process development and at GMP scale. These customizable technologies can be applied separately but can also be combined to design robust, integrated, flexible platforms that support rapid process development and safeguard the quality of life-protecting vaccines, where closed-systems and aseptic processing is essential.

Speakers:
...

Presenter:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Moderator:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.

Covid-19 and the Vaccines Route for Eradicating the Disease

  • Tuesday, Oct 06- 08:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST
  • Thursday, Oct 22 - 08:00 CEST | 11:30 IST | 14:00 SGT | 15:00 JST
  • Tuesday, Oct 06- 08:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST
  • Thursday, Oct 22 - 08:00 CEST | 11:30 IST | 14:00 SGT | 15:00 JST
Duration:
2 Hours
Summary:

This diversity in the type of vaccine antigen, along with the inherent variation in the targets, have created challenges for vaccine manufacturers when compared to a relatively small number of platform processes that exist for other biotherapeutic production processes

Accelerating vaccine development and manufacturing by coupling research advances in vaccine technology with systems that support agility through a Quality by Design approach is critical to deliver life-saving immunizations to those in need globally.

Each class of vaccine presents specific process development and manufacturing challenges, and the scale of production varies depending upon the targeted disease. As a result, there is no single vaccine manufacturing approach.

There are, however, flexible technologies that can meet each of the challenges during process development and at GMP scale. These customizable technologies can be applied separately but can also be combined to design robust, integrated, flexible platforms that support rapid process development and safeguard the quality of life-protecting vaccines, where closed-systems and aseptic processing is essential.

Speakers:
...

Presenter:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Moderator:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.

Register Now

If you would like to attend a webinar, please complete the form below and click the “Register Now" button.